Aquestive Therapeutics (NASDAQ:AQST) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.15) by 53.33 percent. This is a 70.83 percent increase over losses of $(0.24) per share from the same period last year. The company reported quarterly sales of $14.446 million which beat the analyst consensus estimate of $10.896 million by 32.58 percent. This is a 65.67 percent increase over sales of $8.720 million the same period last year.